GlassScriptPhysician profile
Lisa Endanattu
NPI 1639894793
$6,227.25
in general payments reported to CMS, 2019-2025
28 companies · $2,180 in 2025
The $2,180 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.47 · 2023: $1,757 · 2024: $2,247 · 2025: $2,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,970 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,969.53 |
| Education | $215.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,026.59 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $997.67 | 2022-2025 | Winlevi, Blu-U, Odomzo |
| Incyte Corporation | $491.04 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $436.50 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $315.12 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $309.76 | 2023-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $304.32 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $301.56 | 2023-2024 | |
| Genzyme Corporation | $292.26 | 2023-2024 | |
| Janssen Biotech, INC. | $284.84 | 2024-2025 | Tremfya |
| Amgen INC. | $247.64 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $223.02 | 2023-2025 | Aklief, Twyneo |
| Pfizer INC. | $202.80 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $182.98 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $173.61 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $102.75 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.29 | 2023 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.86 | 2023 | Jublia, Arazlo, Duobrii |
| Leo Pharma INC. | $38.62 | 2023 | Adbry |
| Organon LLC | $37.27 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $34.79 | 2025 | |
| Almirall LLC | $20.92 | 2025 | Klisyri |
| Lnhc, INC | $17.91 | 2025 | Zelsuvmi |
| Kyowa Kirin, INC. | $16.98 | 2023 | Poteligeo |
| Helsinn Therapeutics (U.S.), INC. | $16.30 | 2023 | Valchlor |
| Blueprint Medicines Corporation | $15.51 | 2024 | Ayvakit |
| Verrica Pharmaceuticals INC. | $14.48 | 2023 | Ycanth |
| Botanix Sb INC | $13.86 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Endanattu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.